Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results From a Multicenter Study

Kai Yu, Andreas Ladefoged Ebbehøj, Hiba Obeid, Anand Vaidya, Tobias Else, Heather Wachtel, Ailsa Maria Main, Esben Søndergaard, Louise Lehmann Christensen, Christofer Juhlin, Jan Calissendorff, Debbie L. Cohen, Bonita Bennett, Marianne Skovsager Andersen, Catharina Larsson, Madson Q. Almeida, Lauren Fishbein, Stephen A. Boorjian, William F. Young, Irina Bancos*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

11 Citationer (Scopus)

Abstract

Context: Urinary bladder paraganglioma (UBPGL) is rare. Objective: We aimed to characterize the presentation and outcomes of patients diagnosed with UBPGL. Methods: We conducted a multicenter study of consecutive patients with pathologically confirmed UBPGL evaluated between 1971 and 2021. Outcomes included repeat bladder surgery, metastases, and disease-specific mortality. Results: Patients (n=110 total; n=56 [51%] women) were diagnosed with UBPGL at a median age of 50 years (interquartile range [IQR], 36-61 years). Median tumor size was 2 cm (IQR, 1-4 cm). UBPGL was diagnosed prior to biopsy in only 37 (34%), and only 69 (63%) patients had evaluation for catecholamine excess. In addition to the initial bladder surgery, 26 (25%) required multiple therapies, including repeat surgery in 10 (9%). Synchronous metastases were present in 9 (8%) patients, and 24 (22%) other patients with UBPGL developed metachronous metastases at a median of 4 years (IQR, 2-10 years) after the initial diagnosis. Development of metachronous metastases was associated with younger age (hazard ratio [HR] 0.97; 95% CI, 0.94-0.99), UBPGL size (HR 1.69; 95% CI, 1.31-2.17), and a higher degree of catecholamine excess (HR 5.48; 95% CI, 1.40-21.39). Disease-specific mortality was higher in patients with synchronous metastases (HR 20.80; 95% CI, 1.30-332.91). Choice of initial surgery, genetic association, sex, or presence of muscular involvement on pathology were not associated with development of metastases or mortality. Conclusions: Only a minority of patients were diagnosed before biopsy/surgery, reflecting need for better diagnostic strategies. All patients with UBPGL should have lifelong monitoring for development of recurrence and metastases.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Endocrinology and Metabolism
Vol/bind107
Udgave nummer10
Sider (fra-til)2811-2821
Antal sider11
ISSN0021-972X
DOI
StatusUdgivet - 2022
Udgivet eksterntJa

Bibliografisk note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved.

Citationsformater